Literature DB >> 30524528

A novel, accelerated method of desensitization in a patient with a documented hypersensitivity reaction to clopidogrel.

Ripple Doshi1, Agei Enoh2, Peter Antonopoulos2, Payman Sattar1,2.   

Abstract

Current standard of care following a percutaneous coronary intervention with stent placement necessitates the use of dual anti-platelet therapy with aspirin and commonly clopidogrel. There is a subset of patients who have a significant clopidogrel allergy and life-threatening hypersensitivity reactions. Desensitization is the process of inducing tolerance to a sensitizing agent via repeated exposure to the agent. There have been previously reported protocols for clopidogrel desensitization. These protocols differ in length and dose escalation and a universally accepted clopidogrel desensitization protocol has yet to be established. We discuss here a novel accelerated approach to clopidogrel desensitization in a patient with a documented hypersensitivity reaction.

Entities:  

Keywords:  Clopidogrel allergy; Desensitization; PCI; Stent

Year:  2010        PMID: 30524528      PMCID: PMC6264946          DOI: 10.1016/j.jccase.2009.12.008

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  9 in total

1.  Desensitization for the management of clopidogrel hypersensitivity: initial clinical experience.

Authors:  Nicholas E Walker; Mary Beth Fasano; Phillip A Horwitz
Journal:  J Invasive Cardiol       Date:  2006-07       Impact factor: 2.022

2.  Rash with both clopidogrel and ticlopidine in two patients following percutaneous coronary intervention with drug-eluting stents.

Authors:  Kathy Makkar; Robert L Wilensky; Maureen Burke Julien; Howard C Herrmann; Sarah A Spinler
Journal:  Ann Pharmacother       Date:  2006-05-09       Impact factor: 3.154

3.  Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.

Authors:  S R Steinhubl; W A Tan; J M Foody; E J Topol
Journal:  JAMA       Date:  1999-03-03       Impact factor: 56.272

4.  Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.

Authors:  Ioannis Iakovou; Thomas Schmidt; Erminio Bonizzoni; Lei Ge; Giuseppe M Sangiorgi; Goran Stankovic; Flavio Airoldi; Alaide Chieffo; Matteo Montorfano; Mauro Carlino; Iassen Michev; Nicola Corvaja; Carlo Briguori; Ulrich Gerckens; Eberhard Grube; Antonio Colombo
Journal:  JAMA       Date:  2005-05-04       Impact factor: 56.272

5.  Immunologic observations during desensitization and maintenance of clinical tolerance to penicillin.

Authors:  R Naclerio; E A Mizrahi; N F Adkinson
Journal:  J Allergy Clin Immunol       Date:  1983-03       Impact factor: 10.793

6.  Clopidogrel desensitization after drug-eluting stent placement.

Authors:  Karl F von Tiehl; Matthew J Price; Rafael Valencia; Katherine J Ludington; Paul S Teirstein; Ronald A Simon
Journal:  J Am Coll Cardiol       Date:  2007-11-05       Impact factor: 24.094

7.  Antigen-specific desensitization of patients allergic to penicillin.

Authors:  T J Sullivan
Journal:  J Allergy Clin Immunol       Date:  1982-06       Impact factor: 10.793

8.  Basic characteristics of human lung mast cell desensitization.

Authors:  D MacGlashan; L M Lichtenstein
Journal:  J Immunol       Date:  1987-07-15       Impact factor: 5.422

9.  Frequency of allergic or hematologic adverse reactions to ticlopidine among patients with allergic or hematologic adverse reactions to clopidogrel.

Authors:  Juzar O Lokhandwala; Patricia J M Best; Joseph H Butterfield; Kimberly A Skelding; Thomas Scott; James C Blankenship; Jeremy W Buckley; Peter B Berger
Journal:  Circ Cardiovasc Interv       Date:  2009-07-22       Impact factor: 6.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.